Nektar Therapeutics has achieved a significant milestone by initiating its global Phase 3 program, ZENITH AD, for rezpegaldesleukin (rezpeg) in patients with moderate to severe atopic dermatitis. This move signals the advancement of this innovative therapeutic towards regulatory approval, with top-line data from these studies anticipated by mid-2028 and a Biologics License Application (BLA) submission projected for 2029 if results are favorable. Following regulatory discussions with the FDA, Nektar also finalized the blueprint for a singular registrational Phase 3 investigation of rezpeg for alopecia areata, slated to commence in early 2027. The clinical trial designs are informed by promising clinical data collected earlier this year from patients suffering from atopic dermatitis and alopecia areata, aligning with insights from previous regulatory engagements. Nektar's leadership projects that the company's cash reserves will provide financial stability well into the third quarter of 2028, covering the crucial period leading up to the initial Phase 3 data readouts for atopic dermatitis.
The company's financial standing remains robust, boasting over $1 billion in cash and investments at the close of the second quarter of 2026. This strong financial base is partly due to a successful public offering in April 2026, which generated $350 million in net proceeds. For the second quarter of 2026, Nektar reported $10.1 million in non-cash royalty revenue, alongside a net loss of $40.6 million, or $1.23 per share. Research and development expenses for the quarter amounted to $39.1 million, primarily driven by the launch of the Phase 3 ZENITH AD program and manufacturing efforts for rezpegaldesleukin. General and administrative expenses saw a reduction to $12.8 million, attributed to decreased legal costs. Looking ahead, Nektar's management reaffirmed its full-year revenue guidance of $40 million to $45 million for 2026 and provided updated guidance for R&D and G&A expenses, with end-of-year cash projected to be between $815 million and $840 million, an increase from prior forecasts. This financial strength underpins the company's strategic focus on driving rezpegaldesleukin towards BLA submission and exploring further indications, including type 1 diabetes and novel TNFR2 agonist programs like NKTR-0165 and NKTR-0166.
Nektar is strategically exploring rezpeg's potential across a broader range of autoimmune conditions, including its ongoing Phase 2 study in type 1 diabetes through TrialNet. The company's unique mechanism, targeting regulatory T cells, sets rezpeg apart by acting upstream of various inflammatory pathways to re-establish immune equilibrium, offering a distinct advantage over existing treatments that often target single downstream inflammatory mediators. Preliminary data suggest rezpeg's efficacy, favorable safety profile, and prolonged durability, with responses deepening over time. The atopic dermatitis market presents a significant opportunity, with over 15 million Americans affected by moderate to severe disease, and a substantial unmet need for effective systemic therapies. Similarly, the alopecia areata market is projected to reach $5 billion by 2033, despite the safety concerns associated with current JAK inhibitor treatments. Nektar's market research indicates a strong preference among physicians for rezpeg's novel mechanism of action, favorable safety profile, and less frequent dosing regimens, positioning it as a potential preferred first-line option for patients with severe forms of these conditions. The company is committed to initiating new clinical studies for additional rezpegaldesleukin indications before the end of 2026, further cementing its commitment to addressing critical unmet medical needs.
Nektar Therapeutics' commitment to innovation and patient well-being shines through its robust clinical development pipeline and strategic financial management. By pushing the boundaries of scientific discovery and addressing significant unmet needs in chronic diseases, the company exemplifies a forward-thinking approach to healthcare. This dedication not only promises improved outcomes for countless patients but also reinforces the vital role of persistent research and development in fostering a healthier future for all.
